Pharsight

NOVO NORDISK AS patents facing oppositions

Top patents of NOVO NORDISK AS facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP3448416B1 10 Aug, 2022 Semaglutide in cardiovascular conditions Apr, 2037 8
EP2863895B1 14 Apr, 2021 Tablet formulation comprising a peptide and a delivery agent Jun, 2033 7
EP1687019B1 22 Nov, 2017 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Nov, 2024 6
EP3423082B1 04 Aug, 2021 Liraglutide in cardiovascular conditions Mar, 2037 5
EP3300721B1 06 Mar, 2019 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Nov, 2024 5
EP2827845B1 26 Dec, 2018 Compositions comprising a delivery agent and preparation thereof Mar, 2033 5
EP3326620B1 04 Mar, 2020 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid Dec, 2031 4
EP2866825B1 08 Apr, 2020 Use of long-acting glp-1 peptides Jun, 2033 3
EP2494983B1 24 Apr, 2019 Stable formulations of glp-1 Nov, 2025 2
EP2950853B1 15 Mar, 2017 A non-axial working end-of content mechanism and an injection device comprising the same Jan, 2034 2
EP3634468B1 14 Dec, 2022 Solid compositions for oral administration Jun, 2038 1
EP3071262B1 08 Apr, 2020 Rotary sensor assembly with space efficient design Nov, 2034 1
EP2729202B1 16 May, 2018 Drug delivery injection pen with add-on dose capturing and display module Jul, 2032 1
EP2958612B1 11 Apr, 2018 Drug delivery device with dose capturing module Feb, 2034 1